Last reviewed · How we verify
FOLFRINOX
FOLFRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells.
FOLFRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells. Used for Metastatic pancreatic cancer, Metastatic colorectal cancer, Gastric cancer.
At a glance
| Generic name | FOLFRINOX |
|---|---|
| Also known as | Irinotecan,Oxaliplatin and 5-FU |
| Sponsor | Zhejiang Cancer Hospital |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFRINOX combines 5-fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and irinotecan. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; oxaliplatin is a platinum agent that creates DNA crosslinks; and irinotecan inhibits topoisomerase I. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic pancreatic cancer
- Metastatic colorectal cancer
- Gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
- Mucositis
Key clinical trials
- CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (PHASE1, PHASE2)
- A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status (PHASE3)
- A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |